Professor Ann Daly
Professor of Pharmacogenetics and Associate Dean for Internationalisation (Faculty of Medical Sciences)

  • Email: a.k.daly@ncl.ac.uk
  • Telephone: +44 (0) 191 208 7031
  • Address: Institute of Cellular Medicine
    Medical School
    Newcastle University
    Newcastle upon Tyne NE2 4HH
    UK


BA (Class 2.1) in Biochemistry (1978, University of Dublin)

PhD in Biochemistry (1982, University of Dublin)

FBPhS (2012)

 

Present appointment

Professor of Pharmacogenetics, Institute of Cellular Medicine, Newcastle University, UK (since August 2004)

Previous appointments

Senior Lecturer, School of Clinical and Laboratory Sciences, Newcastle University (1998-2004).

Lecturer, Department of Pharmacological Sciences, Newcastle University (1992-1998).

Senior Research Associate, Department of Pharmacological Sciences, Newcastle University (1989-1992).

Research Associate, Medical Molecular Biology Group and Department of Dermatology, Newcastle University (1984-1989).

Postdoctoral Research Assistant, Department of Molecular Biology, University of Geneva, Switzerland (1982-1984).

Other current appointments

Chair IUPHAR (The International Union of Basic and Clinical Pharmacology) Drug Metabolism and Transporter section executive board (2014-2018)

Member IUPHAR Pharmacogenetics subcommittee

Committee member UK Pharmacogenetics and Stratified Medicine Network (since 2014)

Editor, CYP alleles website (http://www.imm.ki.se/CYPalleles/)

Executive Editor, British Journal of Clinical Pharmacology

Editorial Board Member, Clinical Pharmacology & Therapeutics, Pharmacogenetics & Genomics, Journal of Pharmacology & Experimental Therapeutics, Pharmacogenomics, Pharmacogenomics Journal

Research Interests

Pharmacogenetic studies on the discovery of novel human genetic polymorphisms, their functional significance and their relationship to outcome of drug therapy, susceptibility to adverse drug reactions and susceptibility to complex diseases. These studies are central to the area of personalised (stratified) medicine and
a key aim is to translate our findings to simple tests that can be used to determine the most appropriate drug treatment on an individual basis.

I coordinate the iDILIC network on genetics of drug-induced liver injury ( http://www.ncl.ac.uk/icm/research/project/4568) and see also (http://www.ncl.ac.uk/numed/about/news/item/newcastle-university-leading-project-on-drug-induced-liver-disease-copy) together with the UK DILIGEN project (www.diligen.org).